DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Assessing small-sized D-fructose-functionalized micelles for active targeting of triple-negative breast cancer
ATR: Active Transport and Retention; CH2Cl2: Dichloromethane; CMC: Critical Micelle Concentration; DAPI: 4′,6-Diamidino-2-Phenylindole; DIC: N,N′-Diisopropylcarbodiimide; DLS: Dynamic Light Scattering; DMF: Dimethylformamide; DMSO: Dimethyl Sulfoxide; DXT: Docetaxel; EPR: Enhanced Permeability and Retention; FACS: Fluorescence-Activated Cell Sorting; FRUC: D-fructose; GLUT5: Glucose Transporter type 5; H&E: Haematoxylin and Eosin; HPLC: High-Performance Liquid Chromatography; HRMS: High-Resolution Mass Spectrometry; IgG: Immunoglobulin G; NMR: Nuclear Magnetic Resonance; NR: Nile Red; PDA: Polydiacetylene; PCDA: Pentacosadiynoic Acid; PEG: Polyethylene Glycol; PBS: Phosphate Buffered Saline; ROI: Region of Interest; SD: Standard Deviation; TEM: Transmission Electron Microscopy; TFA: Trifluoroacetic Acid; THF: Tetrahydrofuran; TNBC: Triple-Negative Breast Cancer., Chemicals and CAS Registry Numbers
.
azide 12596-60-0, 14343-69-2
dimethyl sulfoxide 67-68-5
docetaxel 114977-28-5
fructose 30237-26-4, 57-48-7, 7660-25-5, 77907-44-9
Show more, Triple-negative breast cancer (TNBC) is one of the most aggressive and clinically challenging subtypes of breast cancer. Its high heterogeneity and lack of actionable molecular targets limit therapeutic options, leading to poor patient outcomes. Given the reported overexpression of the fructose transporter GLUT5 (Glucose Transporter type 5) in breast cancer cells, D-fructose (FRUC) has been proposed as a ligand for active targeting; however, its effectiveness remains uncertain. Here, we investigate passive and fructose-mediated active targeting of TNBC using small-sized supramolecular micelles in vitro and in vivo. We designed two micelle formulations, one incorporating a D-fructose headgroup, using amphiphiles composed of pentacosadiynoic acid as the hydrophobic core and polyethylene glycol as a spacer. These micelles (∼10 nm) were characterized by nuclear magnetic resonance, electron microscopy, and dynamic light scattering, and their stability was confirmed under various conditions. Cellular internalization studies, flow cytometry, and confocal microscopy revealed that PEGylated micelles exhibited superior intracellular accumulation compared to fructose-functionalized micelles, suggesting that D-fructose may hinder endocytic uptake rather than enhance it. In vivo biodistribution analysis in tumor-bearing mice showed similar tumor accumulation for both formulations, with FRUC-Mic exhibiting a transiently higher presence at 1-h post-administration, though this difference was not statistically significant. Although this study does not validate D-fructose as an effective ligand for active targeting, both micelle formulations showed key advantages, including Immunoglobulin G-sized particles, high stability, and facile synthesis, enabling scalable production and clinical translation. Moreover, their ability to solubilize, stabilize, and deliver hydrophobic dyes and cytotoxic agents underscores their potential as theranostic nanoplatforms for TNBC treatment., Financial support was provided by the Spanish Ministry of Science and Innovation (Ref: PID2020-119949RB-I00 and PID2023-152689OB-I00 to NK), the Andalusian Ministry of Economy, Science and Innovation cofinanced by the European Regional Development Fund (ERDF) from FEDER and the European Social Fund (ESF) (PY20_00882, CV20-04221 and “POSTDOC_21_00594”), the CSIC (CSIC-COV19-047) the PAIDI Program from the Andalusian Government (FQM-313). The COST action CA-18132 “Functional Glyconanomaterials for the Development of Diagnostic and Targeted Therapeutic Probe” is also acknowledged. Financial support was provided by the Andalusian Ministry of Economy, Science and Innovation in the framework of the Plan Andaluz de Investigación, Desarrollo e Innovación (PAIDI 2020, programme 54a “Investigación científica e innovación”, “POSTDOC_21_00594”), the Fundación Vencer el Cancer (B.R.G. and V.C), the Spanish association against the Cancer AECC investigator grant (INVES20033COMA to V.C.) and the Marie Skłodowska-Curie Individual Fellowship (MSCA-IF Onco-inflammation 101026137 to V.C.). In vivo and ex vivo optical/X-ray images were acquired at the ICTS “NANBIOSIS”, specifically within the U28 Unit at the Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND)., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-119949RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-152689OB-I00
,
EC / H2020 PY20_00882
,
EC / H2020 CV20-04221
,
EC / H2020 POSTDOC_21_00594
DOI: http://hdl.handle.net/10261/397828, https://api.elsevier.com/content/abstract/scopus_id/105011150976
HANDLE: http://hdl.handle.net/10261/397828, https://api.elsevier.com/content/abstract/scopus_id/105011150976